Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis

References

• Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92.
   PubMed Web of Science ®Google Scholar
• De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005; 52(8):2461–9.
   PubMedGoogle Scholar
• Rutgers A, Kallenberg CG. Refractory vasculitis. Autoimmun Rev. 2011;10(11):702–6.
   PubMedGoogle Scholar
• Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al.; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44.
   PubMedGoogle Scholar
• Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9(5):842–52.
   PubMedGoogle Scholar
• Kosits C, Callaghan M. Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma. Oncol Nurs Forum. 2000;27(1):51–9.
   PubMedGoogle Scholar
• Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol. 2012;8(9):505–14.
   PubMedGoogle Scholar
• Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009;4(3):579–87.
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–81.
   PubMed Web of Science ®Google Scholar
• Shin JI, Eisenhut M. A beneficial effect of rituximab on autoimmune thrombotic thrombocytopenic purpura: just a B-cell depletion? J Allergy Clin Immunol. 2014;133(2):600.
   PubMedGoogle Scholar
• Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52–7.
   PubMedGoogle Scholar
• Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.
   PubMed Web of Science ®Google Scholar
• Lovric S, Erdbruegger U, Kümpers P, Woywodt A, Koenecke C, Wedemeyer H, et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant. 2009;24(1):179–85.
   PubMedGoogle Scholar
• Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71(3):327–33.
   PubMedGoogle Scholar
• Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther. 2013; 15(5):R133.
   PubMedGoogle Scholar
• Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, et al.; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013;65(9):2441–9.
   PubMedGoogle Scholar
• Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–32.
   PubMed Web of Science ®Google Scholar
• Information for Healthcare Professionals: Rituximab (marketed as Rituxan) FDA ALERT [12/2006] http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126519.htm Accessed on 24th January 2007.
   Google Scholar
• Nakabayashi K, Hashimoto H. Microscopic polyangiitis. In: Hashimoto H, (ed.). Clinical Manual for Vasculitis (in Japanese). Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan; 2002. pp. 24–6.
   Google Scholar
• Yoshida M. Wegener's granulomatosis. In: Hashimoto H, (ed.). Clinical Manual for Vasculitis (in Japanese). Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan; 2002. pp. 30–4.
   Google Scholar
• Tsusaka N. Allergic granulomatous angiitis. In: Hashimoto H, (ed.). Clinical Manual for Vasculitis (in Japanese). Tokyo: Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan; 2002. pp. 27–9.
   Google Scholar
• Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol. 2002;109(4):581–91.
   PubMedGoogle Scholar
• Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford). 2014;53(3):532–9.
   PubMedGoogle Scholar
• Specks U. Biologic agents in the treatment of granulomatosis with polyangiitis. Cleve Clin J Med. 2012;79(Suppl 3):S50–3.
   PubMedGoogle Scholar
• Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. B-cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006;176(10):6147–54.
   PubMedGoogle Scholar
• Besada E, Nossent JC. Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis? Clin Rheumatol. 2013;32(11):1677–81.
   PubMedGoogle Scholar
• Mahr A, Heijl C, Le Guenno G, Faurschou M. ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol. 2013;27(1):45–56.
   PubMedGoogle Scholar
• Pankhurst T, Savage CO, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology. 2004; 43(12):1532–5.
   PubMed Web of Science ®Google Scholar
• Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002;100(1):82–5.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann R, Furst DE, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558–67.
   PubMed Web of Science ®Google Scholar
• Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896–908.
   PubMed Web of Science ®Google Scholar
• Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, et al. Decreased CD5 + B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013;8(3):382–91.
   PubMedGoogle Scholar
• Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, Grasland A, Zoulim A, LE Guen J, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012;39(1):125–30.
   PubMedGoogle Scholar
• Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology. 2013;52(11):2041–7.
   PubMedGoogle Scholar
• de Lind van Wijngaarden RA, van Rijn L, Hagen EC, Watts RA, Gregorini G, Tervaert JW, et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol. 2008;3(1):237–52.
   PubMedGoogle Scholar
• Kobayashi S. Epidemiology about the ANCA-related vasculitis (in Japanese). Rheumatica. 2008;40(1):1–7.
   Google Scholar